Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

6.140 +0.290 (+4.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,900
Open 6.050
Bid (Size) 5.800 (1)
Ask (Size) 7.400 (1)
Prev. Close 5.850
Today's Range 5.960 - 6.250
52wk Range 3.210 - 10.69
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
-11.78%
-11.78%
1 Month
-9.57%
-9.57%
3 Month
-24.20%
-24.20%
6 Month
+5.32%
+5.32%
1 Year
+59.48%
+59.48%

More News

Read More
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
Via InvestorPlace
Coya Therapeutics
Via Talk Markets
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
From Coya Therapeutics, Inc.
Via Business Wire
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Via Benzinga
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
From Coya Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.